Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs)

被引：0
|
作者：
Duan, Heying [1 ]
Girod, Bradley [1 ]
Ninatti, Gaia [1 ]
Ferri, Valentina [1 ]
Kunz, Pamela [2 ]
Fisher, George [3 ]
Moradi, Farshad [1 ]
Davidzon, Guido [4 ]
Franc, Benjamin [1 ]
Iagaru, Andrei [5 ]
Aparici, Carina Mari [1 ]
机构：
[1] Stanford Univ, Div Nucl Med, Radiol, Stanford, CA 94305 USA
[2] Stanford Canc Ctr, Stanford, CA USA
[3] Stanford Univ, Oncol, Stanford, CA 94305 USA
[4] Stanford Univ, Radiol Nucl Med, Stanford, CA 94305 USA
[5] Stanford Univ, Stanford, CA 94305 USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2020年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1442
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)
    Duan, H.
    Girod, B.
    Ninatti, G.
    Ferri, V
    Kunz, P.
    Fisher, G.
    Moradi, F.
    Davidzon, G.
    Franc, B.
    Lagaru, A.
    Aparici, Mari C.
    [J]. NEUROENDOCRINOLOGY, 2020, 110 : 252 - 252
  • [2] Evaluation of toxicity in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET)
    Duan, H.
    Ferri, V.
    Kunz, P. L.
    Fisher, G. A.
    Moradi, F.
    Davidzon, G. A.
    Franc, B. L.
    Iagaru, A. H.
    Mari, C. Aparici
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S471 - S472
  • [3] Outcomes of peptide receptor radionuclide therapy (PRRT) in metastatic grade 3 neuroendocrine tumors (NETs).
    Lung, Mei Sim
    Hofman, Michael
    Kong, Grace
    Thang, Sue-Ping
    Michael, Michael
    Hicks, Rodney J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs): A United States Experience
    Katona, Bryson
    Riff, Brian
    Soulen, Michael
    Pryma, Daniel
    Bennett, Bonita
    Wild, Damian
    Nicolas, Guillaume
    Teitelbaum, Ursina
    Metz, David
    [J]. PANCREAS, 2017, 46 (03) : 439 - 439
  • [5] Systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)
    Teran Brage, E.
    Campana-Diaz, E.
    Navarro Martin, M.
    Garcia-Talavera, P.
    Lopez Gutierrez, A.
    Reguera Puertas, P.
    Rama-Alonso, S.
    Roldan Ruiz, J.
    Posado Dominguez, L.
    Pablo Martin, E.
    Lozano Mejorada, R.
    Fonseca Sanchez, E.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S95 - S95
  • [6] Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs)
    Baum, Richard P.
    Wang, Peipei
    Jakobsson, Vivianne
    Zhao, Tianzhi
    Schuchardt, Christiane
    Khong, Pek-Lan
    Zhang, Jingjing
    [J]. THERANOSTICS, 2024, 14 (01): : 133 - 142
  • [7] Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs) in a United States (US) Population
    Katona, Bryson W.
    Riff, Brian P.
    Soulen, Michael C.
    Pryma, Daniel A.
    Bennett, Bonita J.
    Wild, Damian
    Nicolas, Guillaume
    Teitelbaum, Ursina R.
    Metz, David C.
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S208 - S209
  • [8] Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues
    Bodei, L.
    Pepe, G.
    Paganelli, G.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2010, 14 (04) : 347 - 351
  • [9] Overall outcome of peptide receptor radionuclide therapy (PRRT) in treatment metastatic progressive neuroendocrine tumors (NETs): Survival, toxicity and prognostic factors
    Alsadik, S. R.
    Gnanasegaran, G.
    Chen, L.
    Toumpanakis, C.
    Caplin, M.
    Navalkissoor, S.
    [J]. JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 171 - 171
  • [10] Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT)
    Otte, Andreas
    [J]. HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2016, 19 (02): : 182 - 182
12345